Abstract
One major challenge in the development of CO as a therapeutic agent is its controllable delivery in a pharmaceutically acceptable form. Herein, we describe for the first time a general chemical strategy to esterase-sensitive organic CO-prodrugs.
MeSH terms
-
Animals
-
Carbon Monoxide / chemistry
-
Carbon Monoxide / metabolism*
-
Carbon Monoxide / pharmacology
-
Click Chemistry*
-
Dose-Response Relationship, Drug
-
Esterases / metabolism*
-
Lipopolysaccharides / antagonists & inhibitors
-
Lipopolysaccharides / pharmacology
-
Mice
-
Molecular Structure
-
Prodrugs / chemistry
-
Prodrugs / metabolism*
-
Prodrugs / pharmacology
-
RAW 264.7 Cells
-
Structure-Activity Relationship
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
-
Tumor Necrosis Factor-alpha / metabolism
Substances
-
Lipopolysaccharides
-
Prodrugs
-
Tumor Necrosis Factor-alpha
-
Carbon Monoxide
-
Esterases